British pharmaceutical company AstraZeneca posted a net profit of $748 million (€732 million) in the first half of this year, down 65% from the same period in 2021, the company said this Friday.
Covid-19 vaccine sales boosted the company’s results in the first half of last year, with turnover up 23% and up 43% in the first half of this year, despite lower profits.
In a report sent to the London Stock Exchange this Friday, AstraZeneca notes that revenue reached $22,161 million (€21,670 million at current exchange rates) between January and June.
The drug maker said operating profit also fell 53%, from $3,022m (€2,948m) last year to $1,417m (€1,382m) in 2022.
He also revealed that net debt stood at $24,689 million (€24,095 million) as of June 30, down from $11,721 million (€11,438 million) at the end of June 2021.
By business, AstraZeneca’s oncology generated revenue of US$7,454 million (€7,282 million) in the first half, up 18% and accounting for 34% of total revenue.
Immunotherapy and vaccine products, including Covid-19 drug Vaxzevria, generated 13% of total revenue with $2,795 billion (€2,730 million) in revenue.
“It is estimated that Vaxzevria saved more than six million lives in the first year of vaccination, and Evushheld protected hundreds of thousands of people, allowing them to return to normal life. Evusheld continues to show activity against new variants. Pascal Soriot, Chief Executive Officer of AstraZeneca, in his report.
Author: Lusa
Source: CM Jornal
